Replies to post #121400 on Biotech Values

[DewDiligence]

The handover from SNY to GSK is one reason Arxitra never attained market acceptance commensurate with the technical merits of the drug.

[investorgold2002]

sodrock - i never contended that arixtra poses competition to lovenox....my discussion was more on ANDA backlog

March 2009 - dr reddy's filed ANDA under GIVE initiative(supposedly should halve the time for ANDA approval compared to regular ANDA)

still not approved. Now they continue (even in May 2011) to say there are no issues FDA have raised....

i hope and wish FDA hired some 1000 extra reviewers. hope the government realizes it could potentially save $billions/year if they invested 50-100m